Herbas VPB

Print
EN | LT
Supplementary protection
LT - Anti-P-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
EN - Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
SPC
(11) Number of the document C 2662091
(68) Number of the document 2662091
(21) Application number for Supplementary Protection Certificate PA 2021 506
(22) Date of filing the application 2021-04-13
(41) Date of publication of the application 2021-05-10
Date of publication of SPC 2022-10-10
(24) Date of coming into effect of SPC 2027-12-01
Applicant
(71) Novartis AG, Lichtstrasse 35, 4056 Basel, CH
Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK 73104, US
Grantee
(73) Novartis AG, Lichtstrasse 35, 4056 Basel, CH
Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK 73104, US
Attorney or representative
(74) Jurga PETNIŪNAITĖ, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
(93) EU/1/20/1476, 2020-10-28
Calculated date of expiry of the SPC
(94) 2032-11-30
Name of the product protected by the basic patent
(95) Krizanlizumabas
Legal status
SPC granted
Last update date 2022-10-07